Greetings, and welcome to the INmune Bio Second Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce to you Mr. David Moss, CFO of INmune Bio. David, thank you. The floor is yours.

Thank you, John, and good afternoon, everybody. We thank you for joining us for the call for Immune Bio's second quarter 2023 financial results. With me on the call, actually sitting right next to me is Dr. RJ Tesi, CEO of Immu Bio, who will provide an update on our two platforms, XPro and INKmune. Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filing with the SEC. There's no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as of the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligation to update these forward-looking statements to reflect future information events or circumstances. With that behind us, now I'd like to turn the call over to Dr. RJ Tesi, CEO of Immuno Bio. RJ?

Thank you, David, and thank you, everyone for joining the call. As usual, I will arrange my remarks to highlight the key takeaways for the second quarter and subsequent period, and provide updates on our platform programs. I will start by reviewing our developments with XPro and INKmune before I pass it back to David to discuss financial results and provide an update on upcoming and new milestones. We will then move to Q&A. During the second quarter, our primary focus remained enrollment of patients into the Phase 2 blinded randomized trial in patients with early Alzheimer's disease with inflammation and increasing the geographic footprint of that trial. We are going global. Expanding the geographic footprint has been slowed by staffing problems at regulatory authorities in some jurisdictions. I believe this is a hangover from the COVID era. For instance, one country has -- is a 120 days past the response time required by law. But there's nothing you can do about the problem. We just deal with it and answer their requests as needed. Enrollment continues to accelerate, and we are encouraged to see patients finish the trial and opt to continue treatment under the Phase 2 open-label extension program. I remind you the OLE or the Open Label Extension provides two additional bites at the apple, if I may. One-third of the patients entering the Open Label Extension have been on placebo that is they've not received XPro. These patients now have an opportunity to respond to XPro therapy. We should be able to capture that data. Patients who received XPro the two-thirds who had been on active drug during the trial, we'll continue on the drug and provides data for long-term efficacy and safety follow-up, important issues for the company, investors, clinical teams, potential partners and the…

Thank you, RJ. I'll provide a brief overview of our financial results and upcoming milestones before we head to our Q&A session. Net loss attributable to common stockholders for the quarter ended June 30th, 2023, was approximately $6.5 million compared with approximately $6.8 million for the comparable period in 2022. Research and development expenses totaled approximately $4.1 million for the quarter ended June 30th, 2023, compared with approximately $4.2 million for the comparable period in 2022. General and administrative expense was approximately $2.3 million for the quarter ended June 30th, 2023, compared with approximately $2.2 million for the comparable period in 2022. At the end of June 30th, 2023, the company had cash and cash equivalents of approximately $47.8 million. Based on our current operating plan, we believe our cash is sufficient to fund our operations into late-2024. As of August 7th, 2023, the company had approximately 18 million shares of common stock outstanding. As highlighted in the prior quarter's investor call, we continue to focus on achieving our primary clinical trial objectives, while remaining cost prudent with the potential to recover a portion of R&D expenses in Australia and, to a lesser extent, the UK. Now I'd like to move on and list our upcoming important milestones. Top line results for our Phase 2 early ADi trial in patients with inflammation in Alzheimer's disease is expected in late-2024. We will initiate a Phase 2 trial of XPro in patients with Treatment Resistant Depression upon resolution of the FDA's manufacturing review. We've been working relatively hard on that. Additional, open-label Phase 1 trial of INKmune in high-risk MDS/AML in 2023 and early 2024. Initiation of a Phase 1/2 program in metastatic castration-resistant prostate cancer, will begin in the second half of this year. Finally, we continue to pursue business development partnership opportunities, and there can be no assurances that the company will complete any transactions as they are complex and very difficult. We have two great platforms and as a small company. We will try to expand the applications of these platforms in areas we do not have the resources or expertise to pursue ourselves, in order to benefit shareholders. Naturally, we'll update investors should material business development events curve. At this point, I'd like to thank you for your time and attention. And I'd like to turn it back to John, our operator to poll for questions. John?

Thank you, sir. At this time, we'll be conducting a question-and-answer session. [Operator Instructions] And the first question comes from the line of Joel Beatty with Baird. Please proceed with your question.

Great. Thanks for the update and for taking my questions. The first one is on the ongoing FDA manufacturing review. Could you provide a little bit more detail there on what is needed to get that resolved?

Yes. So thanks, Joel. So it's now 15 months since we received -- maybe 14 months since we received the clinical hold. And really, I divide this into two halves. It took us a long time to understand exactly what the FDA was asking for. As you know, both Canada and Australia were -- are fine with the new Xpro that we've made is being used to treat patients and both of those are regulatory jurisdictions. And we with the way the communication happens with the FDA, which is not very efficient, it took seven months for us to reach an agreement with the FDA, what the problem was and what the solution was. So I can promise you that was extremely frustrating for us and as it was for investors. Since then, we have been executing against their request, once again, scratching our heads, little confused why they are preventing us from treating patients in the US despite the fact the drug has been used in the US before for COVID trials and is being used in both in the -- in Canada and Australia. But that is the nature of working under the regulatory authority of the FDA. We expect to give them everything they need to get us off clinical hold and time for us to receive that hoped for safe to proceed e-mail before the end of the year. If I sound a little bit less than hyper confident is just because it's the FDA. And you never know the score until the end of the whistle is blown. So it's been frustrating for you. It's frustrating for us, but the drug gets fine. We're using it in two venues and new patients are going on frequently.

And the next question comes from the line of Thomas Shrader with BTIG. Please proceed with your question.

Hey. Good afternoon. This is Sung [ph] calling in for Tom and thanks for taking our questions. So I have two questions. First is regarding Alzheimer and more of a big picture question. Thinking about a pricing for a new drug, if a new drug does not require ARIA monitoring, do you believe that, that will allow for premium pricing pruning cost savings from the MRIs? And then the second question is following the recent FDA decision on the competitor's drug in MDD over the weekend, how does that help you think about enrichment strategy for TRD trial? And can the level TNF can be used here? Thank you.

Yes. So thank you. Very two good questions. So the current estimate for the cost of care -- the cost of receiving an anti-amyloid drug for the first year is $82,000, A little more than US$82,000. That's -- only a one-third of that is the cost of the drug. So two-thirds of that is really all of the safety monitoring and what's needed for diagnosis of the disease. We believe that XPro will not have that burden. In other words, right now, our enrollment criteria include basically a set of blood tests, which are all relatively cheap, nothing fancy, can be done virtually in any lab in the country. and an MRI scan that requires some set of reading, but that is not expensive. There's no PET scans and there's no need for -- at least as we envision it today, there's no need for additional follow-up MRI scans. So yes, you know how pharmaceutical pricing works. The first drug company sets the price, which has been done. And then you can adjust the pricing based on whether you're better. We think if we do meet our clinical goal of stabilizing cognitive decline that allows us for premium pricing. And I would expect that premium pricing would come well within that $82,000 bracket, although don't hold me to that, we're a little ways off from that decision. But the bottom line is the current drugs are difficult to use. They're complicated. I think their uptake is going to be somewhat -- will be slow because of that sophistication needed for managing those patients and the resources, such as MRI scans, which are going to be needed for those managing those patients. As far as the more recent events with major depressive disorder, we found that very interesting and actually quite validating about how we do our CNS drug development. Clearly, although I've not seen the data, I'm not going to comment on it, we are very sensitive to the fact that particularly in depression, but in all central nervous system diseases, placebo effects always are what captured you by surprise. And the way to eliminate surprises on the placebo side is to better control your patient enrollment criteria using enrichment factors. The oncologist learned this, 20 years ago. The CNS drug developers have not yet learned it. We take this seriously. And in our Alzheimer's trials, these patients all have neuroinflammation and actually in the trial that we planned in treatment-resistant depression, they will all have neuroinflammation. We believe by using that kind of, shall we say, discipline and enrollment, it will prevent surprises on the placebo end or the placebo response and allow you to really accurately assess the drug's effect on the disease.

Great. Thank you.

At this time, there are no further questions. And now I would like to turn the floor back over to RJ for any closing comments.

Yes. Thank you. So just in summary, XPro is a unique asset in the Alzheimer's therapeutics space. And this became particularly clear when at AAIC this year, where there are a lot of companies have jumped on the anti-inflammatory bandwagon for Alzheimer's. But as many of you know, CJ, as CJ likes to say, CJ is our VP of CNS Drug Development. For those of you who don't know CJ. It's not treating neuroinflammation that's important. It's how you treat neuroinflammation. Many of the anti-inflammatory strategies are what we call glial suppressive. Another is they turn off glial cells, both astroglia or microglia cells. And while that may prevent production of destructive inflammatory cytokines, it doesn't fix the problem because glial cells play a very, very important and active role in the remodeling and repair needed to control and reverse CNS diseases, including Alzheimer's disease. So turning off a dysfunctional glial cell is not a winning strategy. Converting a dysfunctional, destructive glial cell into functioning -- normally functioning glial cells, the Phagocytize Mylan debris promotes synaptic plasticity and improved neurons function is needed for success. So far, we have evidence that XPro plays this role well. And as far as we know, we're the only drug that plays this role. And finally, why is the NK cell base so confusing. We believe it's a pretty simple reason. Everybody has assumed NK cells are like T cells. When in fact, the how and why of NK cells in oncology is a separate and distinct scientific discipline. INKmune is a therapy that solves the three major problems facing today's NK therapies. INKmune therapy leverages the patient's own NK cells to treat their disease. Why make new NK cells when the patient has plenty. INKmune converts the own -- the patient's own NK…

Ladies and gentlemen, that does conclude today's teleconference. You may disconnect your lines at this time. Thank you for your participation. And have a great day.